Clinical Trial

Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)

Study acronym: TDHOME
Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective validation study, multicenter, open-label, single-arm study, evaluating the concordance between capillary microsampling (using the VAMS Mitra device) and venous sampling in patients undergoing CDK4/6 therapy.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-24
notable Primary completion pushed: 2027-12-15 -> 2028-01-23 2026-07-24
minor Completion pushed: 2028-12-15 -> 2029-01-23 2026-07-24
Trial Details
NCT Number NCT07491380
Lead Sponsor Institut Curie
Conditions Breast Cancer
Enrollment 90 participants
Start Date 2026-06-23
Primary Completion 2028-01-23 (estimated)
Study Completion 2029-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-23